![]() ![]() ![]() Sharifi F, Yesil-Celiktas O, Kazan A et al (2020) A hepatocellular carcinoma–bone metastasis-on-a-chip model for studying thymoquinone-loaded anticancer nanoparticles. Hassan S, Sebastian S, Maharjan S et al (2020) Liver-on-a-chip models of fatty liver disease. īoos JA, Misun PM, Michlmayr A et al (2019) Microfluidic multitissue platform for advanced embryotoxicity testing in vitro. Tan K, Keegan P, Rogers M et al (2019) A high-throughput microfluidic microphysiological system (PREDICT-96) to recapitulate hepatocyte function in dynamic, recirculating flow conditions. Ide I, Nagao E, Kajiyama S et al (2020) A novel evaluation method for determining drug-induced hepatotoxicity using 3D bio-printed human liver tissue. ![]() Nie J, Gao Q, Fu J et al (2020) Grafting of 3D bioprinting to in vitro drug screening: a review. įasolino I, Guarino V, Marrese M et al (2018) HepG2 and human healthy hepatocyte in vitro culture and coculture in PCL electrospun platforms. Grant R, Hallett J, Forbes S et al (2019) Blended electrospinning with human liver extracellular matrix for engineering new hepatic microenvironments. Leite SB, Roosens T, El Taghdouini A et al (2016) Novel human hepatic organoid model enables testing of drug-induced liver fibrosis in vitro. īircsak KM, DeBiasio R, Miedel M et al (2021) A 3D microfluidic liver model for high throughput compound toxicity screening in the OrganoPlate(R). Ghaemmaghami AM, Hancock MJ, Harrington H et al (2012) Biomimetic tissues on a chip for drug discovery. Shih HP, Zhang X, Aronov AM (2018) Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications. īenam KH, Dauth S, Hassell B et al (2015) Engineered in vitro disease models. īell CC, Dankers ACA, Lauschke VM et al (2018) Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: a multicenter study. Godoy P, Hewitt NJ, Albrecht U et al (2013) Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Ma Q, Lu AYH (2011) Pharmacogenetics, pharmacogenomics, and individualized medicine. Hauser AS, Chavali S, Masuho I et al (2018) Pharmacogenomics of GPCR drug targets. Hoofnagle JH, Bjornsson ES (2019) Drug-induced liver injury-types and phenotypes. Nat Rev Gastroenterol Hepatol 16(1):57–73. Wong MCS, Huang JLW, George J et al (2019) The changing epidemiology of liver diseases in the Asia-Pacific region. Navarro VJ, Khan I, Bjoernsson E et al (2017) Liver injury from herbal and dietary supplements. Navarro VJ, Barnhart H, Bonkovsky HL et al (2014) Liver injury from herbals and dietary supplements in the US drug-induced liver injury network. Ren X, Xin LT, Zhang MQ et al (2019) Hepatoprotective effects of a traditional Chinese medicine formula against carbon tetrachloride-induced hepatotoxicity in vivo and in vitro. Zhao P, Wang C, Liu W et al (2014) Acute liver failure associated with traditional Chinese medicine: report of 30 cases from seven tertiary hospitals in China*. Asrani SK, Devarbhavi H, Eaton J et al (2019) Burden of liver diseases in the world. ![]()
0 Comments
Leave a Reply. |